Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?
Breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2) is considered to be HER2-positive. The novel HER2- directed antibody drug conjugate, trastuzumab deruxtecan (T-DXd), is formed by covalently joining the monoclonal antibody trastuzumab with the topoisomerase I inhi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hrvatski liječnički zbor
2023-01-01
|
| Series: | Liječnički vjesnik |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/438256 |